Glaxosmithkline Share News (GSK)

GSK sells anaesthetics to Aspen for up to $370 mln

LONDON, Sept 12 (Reuters) - GlaxoSmithKline is to sell its portfolio of anaesthetic drugs to South Africa's Aspen Pharmacare for up to 280 million pounds ($372 million) as part of a drive by the British drugmaker to focus on core therapy areas. The two firms, which have a long history of wo

UPDATE 1-Sanofi, Google parent in $500 mln diabetes joint venture

(Recasts with details, background) PARIS, Sept 12 (Reuters) - French drugmaker Sanofi and Google owner Alphabet's life sciences firm Verily are to invest about $500 million in a diabetes joint venture combining devices with services, an example of growing ties between the pharma and tech

UPDATE 1-Sanofi, Google parent in $500 mln diabetes joint venture

(Recasts with details, background) PARIS, Sept 12 (Reuters) - French drugmaker Sanofi and Google owner Alphabet's life sciences firm Verily are to invest about $500 million in a diabetes joint venture combining devices with services, an example of growing ties between the pharma and tech

GSK's triple drug cuts flare-ups in chronic lung disease

By Ben Hirschler LONDON, Sept 6 (Reuters) - An experimental three-in-one inhaled drug from GlaxoSmithKline significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday. GSK is ahead of rivals AstraZeneca and Novartis in developing

GlaxoSmithKline's Relvar Ellipta shows 'significant' test score for COPD

(ShareCast News) - Tests of a GlaxoSmithKline respiratory drug have found a statistically significant reduction in the rate of attacks suffered by chronic obstructive pulmonary disease (COPD) patients compared to when they receive the standard treatment. The pioneering Salford Lung Study by GSK and

AstraZeneca seeks edge over rivals in severe asthma treatment

* Benralizumab effective given once every 8 weeks * Cuts annual rate of asthma exacerbations by up to half * AZ aims to take on recently launched GSK, Teva drugs By Ben Hirschler LONDON, Sept 5 (Reuters) - AstraZeneca hopes to convince doctors its experimental injection fo

Friday broker round-up

(ShareCast News) - Pearson: JP Morgan reiterates neutral with a target price of 940p. Vodafone: UBS maintains buy with a 310p target. Glaxosmithkline: UBS keeps at neutral with a 1650p target. GKN: Canaccord reiterates buy with a 370p target. Legal & General: Macquarie keeps at neutral with a tar

Sector movers: Vodafone weighs on mobile telecoms

(ShareCast News) - News that CK Hutchison Holdings and VimpelCom had won European Union approval to merge, in the process creating Italy´s biggest wireless telecommunications provider, sent stock in Vodafone sharply lower and its sector gauge with it. Vodafone´s own unit in that Mediterranean countr

LONDON MARKET CLOSE: Stocks Slip As Focus Moves To Fed's Yellen

LONDON MARKET MIDDAY: Stocks Down As Clinton Remarks Hit Pharma Sector

Shire, AstraZeneca and Hikma hit by Hillary Clinton's pharma-bashing

(ShareCast News) - Hikma Pharmaceuticals, Shire and AstraZeneca were among FTSE-listed drug companies slipping lower on Thursday morning, following comments from US presidential favourite Hillary Clinton on pharmaceutical pricing that hit peers across the Atlantic overnight. Clinton joined senators

BUZZ-OncoMed Pharmaceuticals: Set to open at 3-mth low after equity raise

** OncoMed Pharmaceuticals down 15 pct premarket after cancer drug developer prices its follow-on launched after the bell Wed at a steep discount ** If losses hold, stock set to open at lowest levels since early May. On course for biggest one-day pct fall since Jan ** OncoMed offers 5

GSK's ViiV joint venture begins testing new HIV treatment

(ShareCast News) - GlaxoSmithKline's joint venture with Pfizer and Shionogi has begun testing a new two-drug treatment for HIV that looks to reduce the number of medicines people with the virus have to take. The ViiV Healthcare joint venture will test a two-drug regimen of dolutegravir (under the br

Glaxo's ViiV Starts Phase 3 Trial On Two-Drug HIV-1 Treatment

Friday broker round-up

(ShareCast News) - Britvic: Berenberg reiterates buy with a target price of 775p. RSA Insurance: Deutsche Bank maintains hold with a 525p target. GlaxoSmithKline: JP Morgan reiterates neutral with a 1900p target. Amec Foster: Goldman Sachs stays at buy with a 691,1p target. A.G. Barr: Berenberg d